tradingkey.logo
tradingkey.logo
Search

Inotiv Inc

NOTV
Add to Watchlist
0.295USD
-0.014-4.66%
Market hours ETQuotes delayed by 15 min
10.14MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-4.66%

5 Days

+0.20%

1 Month

+20.33%

6 Months

-71.38%

Year to Date

-47.55%

1 Year

-85.55%

TradingKey Stock Score of Inotiv Inc

Currency: USD Updated: 2026-05-14

Key Insights

Inotiv Inc's fundamentals are relatively stable, with industry-average ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 150 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.00.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Inotiv Inc's Score

Industry at a Glance

Industry Ranking
150 / 382
Overall Ranking
272 / 4482
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Inotiv Inc Highlights

StrengthsRisks
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Overvalued
The company’s latest PE is -0.12, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 8.11M shares, decreasing 37.19% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 87.15K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.82.

Analyst Rating

Based on 2 analysts
Buy
Current Rating
3.000
Target Price
+855.41%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Inotiv Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Inotiv Inc Info

Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Ticker SymbolNOTV
CompanyInotiv Inc
CEOLeasure (Robert W)
Websitehttps://www.inotiv.com/
KeyAI